Name: HALOPERIDOL (HaldolR) Classification: antipsychotic, anxiolytic Dose: Intermittent Bolus Dose: 2.5-5 mg as IV infusion q 30 min - q6h Continuous Infusion: 1-10 mg/hr, with additional 1-10 mg bolus prn up to every 30-60 minutes Administration: IV Infusion: 100 mg in 100 ml of dextrose 5% (maximum concentration of 3 mg/ml) Adverse Effects: tachycardia hypotension or hypertension CNS: ataxia, fixed stare, tardive dyskinesia, tardive dystonia, insomnia, restlessness, agitation, seizures exacerbation of psychotic symptoms dry mouth or hypersalivation constipation anemia, leukopenia QT interval prolongation; Torsades de Pointes elevated liver enzymes Drug Interactions: haloperidol + CNS depressants = increased sedation haloperidol + anticholinergic agents = increased anticholinergic effects Monitoring Therapy: blood pressure heart rate QT interval mental status delirum screen liver enzymes muscular tone and signs of extrapyramidal symptoms skin Adult Critical Care Protocol: May be administed IV direct or by IV infusion by a nurse in Adult Critical Care Continuous infusions must be administered by infusion device with pump library enabled. Lynne Kelly, Pharmacist, CCTC Brenda Morgan, Clinical Nurse Specialist, CCTC Last Update: September 20, 2018
